CTOs on the Move

San Clemente Villas By The Sea

www.sclvillas.com

 
San Clemente Villas By The Sea is a San Clemente, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sclvillas.com
  • 660 Camino De Los Mares
    San Clemente, CA USA 92673
  • Phone: 949.489.3400

Executives

Name Title Contact Details

Similar Companies

United American Healthcare Corporation

United American Healthcare Corporation is a Detroit, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BIOCIUS Life Sciences

BIOCIUS Life Sciences is a Wakefield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

iCardiac Technologies

iCardiac Technologies is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Rochester, NY. To find more information about iCardiac Technologies, please visit www.icardiac.com

War Memorial Hospital

War Memorial Hospital is a Sault Sainte Marie, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.